<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790673</url>
  </required_header>
  <id_info>
    <org_study_id>CF102-103HCV</org_study_id>
    <nct_id>NCT00790673</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1</brief_title>
  <official_title>A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating the Safety, Tolerability, Biological Activity, and Pharmacokinetics of Orally Administered CF102 in Subjects With Chronic Hepatitis C Genotype 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Can-Fite BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Can-Fite BioPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will test the hypothesis that CF102 can safely and effectively suppress viral load
      in patients with chronic hepatitis C and high circulating levels of virus. The trial will
      monitor the safety of twice-daily oral dosing with CF102 over a 16-week period; will measure
      changes in viral load during therapy; and will measure blood concentrations of CF102 at
      various time points during dosing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2, randomized, double-blind, placebo-controlled, dose-escalation study of
      subjects with chronic hepatitis C genotype 1. Eligible subjects will be assigned in a 3:1
      ratio (8 subjects in each cohort) to receive qd or bid treatment for 15 days with oral CF-102
      or with placebo. Dose escalation will occur in 2 sequential cohorts.

      The decision to continue dosing within a cohort (eg, Subcohort 1a to Subcohort 1b), or to
      escalate to a new dose level Cohort (eg, Subcohort 1b to Subcohort 2a) will be determined by
      a blinded independent review of safety data. This review will be conducted by a qualified
      Safety Review Committee comprising the medical monitor, the consulting toxicologist, and an
      independent expert clinician.

      For the first 2 cohorts, subjects will return to the study center for follow-up assessments
      on Days 8, 15, and 22. Subjects dosed qd will receive a total of 15 doses of CF-102. Subjects
      dosed bid will receive a total of 29 doses. The 30th dose has been deleted to accommodate PK
      sampling on the morning of Day 16, 24 hours after the last dose of CF-102.

      For the 3rd cohorts, subjects will return to the study center for follow-up assessments on
      weeks 2, 4, 8, 12, 16 and 18.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event Profile of Repeated Dosing of CF102</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Viral Load</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Behavior of CF102 During Repeated Dosing</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Relationship Between Biomarkers of Peripheral Blood Mononuclear Cell Adenosine 3 Receptor (A3R) Expression and Clinical Effects</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CF102 1 mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CF102 1 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CF102 1 mg bid; 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF 102</intervention_name>
    <description>Oral capsules</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Cl-IB-MECA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 60 years of age

          2. Body mass index ≤ 30 kg/m2

          3. Either:

               1. no evidence of cirrhosis, or liver fibrosis corresponding to Metavir Stages 0 to
                  31 on a liver biopsy performed within the past 2 years, or

               2. a score of F0 or F1 on ActiTest-FibroTest performed within the past year.

          4. Child-Pugh score ≤ 5 at Screening

          5. Serologic evidence of chronic hepatitis C-infection (anti-HCV in serum)

          6. HCV plasma RNA ≥ 1 x 105 IU/mL on 2 separate samples obtained during the screening
             period.

          7. HCV genotype 1

          8. The following laboratory values must be documented within the Screening period:

               -  Hemoglobin &gt; 11.0 g/dL for females and &gt; 12.0 g/dL for males

               -  Platelet count &gt; 50 x109/L

               -  Normal serum creatinine

               -  Aspartic aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5-fold the
                  upper limit of normal

               -  International normalized ratio (INR) ≤ 1.3-fold normal

               -  Serum albumin ≥ 3.6 gm/dL

          9. Female subjects cannot be pregnant or breastfeeding and must be either postmenopausal,
             surgically sterile, abstinent, or using 2 proven methods of birth control

         10. Sexually active male subjects must be practicing acceptable methods of contraception
             (eg, vasectomy, use of condom plus spermicide, monogamous relationship with a female
             partner who practices an acceptable method of contraception) during the treatment
             period

         11. Negative serum ß-human chorionic gonadotropin (HCG, females of child-bearing potential
             only)

         12. Provide informed consent

         13. Willing to comply with all study requirements

        Exclusion Criteria:

          1. Positive test at Screening for human immunodeficiency virus

          2. Uncontrolled congestive heart failure (New York Heart Association Classification 3 or
             4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral
             artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3
             months prior to initiation of study drug

          3. History of or ongoing cardiac dysrhythmias requiring treatment, atrial fibrillation of
             any grade, or persistent prolongation of the corrected QT (QTc) (Fridericia) interval
             to &gt; 450 msec for males or &gt; 470 msec for females

          4. Positive results for drugs of abuse at Screening

          5. Donation or loss of more than 400 mL blood within 2 months prior to anticipated dose
             administration

          6. Participation in a clinical study with an investigational drug, biologic, or device
             within 3 months prior to anticipated dose administration

          7. Previous exposure to CF102(Cohorts 1 and 2 only)

          8. Males whose female partner is pregnant

          9. Serum alpha-feto-protein &gt; 50 ng/mL at screening

         10. Any severe, acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration, may interfere with the informed consent process and/or with
             compliance with the requirements of the study, or may interfere with the
             interpretation of study results and, in the investigator's opinion, would make the
             patient inappropriate for entry into this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Silverman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Can-Fite BioPharma Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.canfite.com</url>
    <description>Can-Fite BioPharma</description>
  </link>
  <reference>
    <citation>Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, Barer F, Zabutti A, Perez-Liz G, Del Valle L, Fishman P. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol. 2008 Aug;33(2):287-95.</citation>
    <PMID>18636149</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2008</study_first_submitted>
  <study_first_submitted_qc>November 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <results_first_submitted>March 5, 2015</results_first_submitted>
  <results_first_submitted_qc>March 31, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 15, 2015</results_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Viral hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 CF102 1 mg qd</title>
          <description>CF102 1 mg qd
CF 102: Oral capsules</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2 CF102 1 mg Bid</title>
          <description>CF102 1 mg bid
CF 102: Oral capsules</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3 CF102 1 mg Bid</title>
          <description>CF102 1 mg bid; 16 weeks
CF 102: Oral capsules</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo: Matching placebo capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 CF102 1 mg qd</title>
          <description>CF102 1 mg qd
CF 102: Oral capsules</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2 CF102 1 mg Bid</title>
          <description>CF102 1 mg bid
CF 102: Oral capsules</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3 CF102 1 mg Bid</title>
          <description>CF102 1 mg bid; 16 weeks
CF 102: Oral capsules</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo: Matching placebo capsules</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.3" spread="12.7"/>
                    <measurement group_id="B2" value="54.5" spread="8.43"/>
                    <measurement group_id="B3" value="48.3" spread="12.4"/>
                    <measurement group_id="B4" value="42.1" spread="11.2"/>
                    <measurement group_id="B5" value="47.3" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Event Profile of Repeated Dosing of CF102</title>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 CF102 1 mg qd</title>
            <description>CF102 1 mg qd
CF 102: Oral capsules</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 CF102 1 mg Bid</title>
            <description>CF102 1 mg bid
CF 102: Oral capsules</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 CF102 1 mg Bid</title>
            <description>CF102 1 mg bid; 16 weeks
CF 102: Oral capsules</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: Matching placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event Profile of Repeated Dosing of CF102</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Viral Load</title>
        <time_frame>16 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Behavior of CF102 During Repeated Dosing</title>
        <time_frame>16 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Relationship Between Biomarkers of Peripheral Blood Mononuclear Cell Adenosine 3 Receptor (A3R) Expression and Clinical Effects</title>
        <time_frame>16 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 CF102 1 mg qd</title>
          <description>CF102 1 mg qd
CF 102: Oral capsules</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2 CF102 1 mg Bid</title>
          <description>CF102 1 mg bid
CF 102: Oral capsules</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3 CF102 1 mg Bid</title>
          <description>CF102 1 mg bid; 16 weeks
CF 102: Oral capsules</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo: Matching placebo capsules</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <description>Palpitations</description>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Fatigue</description>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <description>HEADACHE</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="12" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" events="8" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pnina Fishman, PhD</name_or_title>
      <organization>Can-Fite Biopharma</organization>
      <phone>011972 39241114</phone>
      <email>pnina@canfite.co.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

